BRIACELL THERAPEUTICS CORP.: diluted earnings per share
Diluted earnings per share for BRIACELL THERAPEUTICS CORP. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All BRIACELL THERAPEUTICS CORP. financial histories
What this measure means
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
Exact concept: us-gaap:EarningsPerShareDiluted. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2021-08-01 to 2025-07-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2024-08-01 | 2025-07-31 | -62.19 | USD/shares | 2025-10-16 | 10-K · 0001493152-25-018212 |
| 2023-08-01 | 2024-07-31 | -43.68 | USD/shares | 2025-10-16 | 10-K · 0001493152-25-018212 |
| 2022-08-01 | 2023-07-31 | -1.3 | USD/shares | 2024-10-29 | 10-K · 0001493152-24-042743 |
| 2021-08-01 | 2022-07-31 | -1.73 | USD/shares | 2023-10-25 | 10-K · 0001493152-23-038298 |
Related financial histories
- BRIACELL THERAPEUTICS CORP.: total assets
- BRIACELL THERAPEUTICS CORP.: stockholders equity
- BRIACELL THERAPEUTICS CORP.: cash and cash equivalents
- BRIACELL THERAPEUTICS CORP.: net income or loss
- BRIACELL THERAPEUTICS CORP.: operating cash flow
- BRIACELL THERAPEUTICS CORP.: financing cash flow
- BRIACELL THERAPEUTICS CORP.: retained earnings or deficit
- BRIACELL THERAPEUTICS CORP.: basic weighted-average shares
- BRIACELL THERAPEUTICS CORP.: diluted weighted-average shares
- BRIACELL THERAPEUTICS CORP.: basic earnings per share
- BRIACELL THERAPEUTICS CORP.: net property, plant and equipment
- BRIACELL THERAPEUTICS CORP.: share-based compensation expense
- BRIACELL THERAPEUTICS CORP.: operating income or loss
- BRIACELL THERAPEUTICS CORP.: current assets
- BRIACELL THERAPEUTICS CORP.: current liabilities
- BRIACELL THERAPEUTICS CORP.: net finite-lived intangible assets
- BRIACELL THERAPEUTICS CORP.: net current accounts receivable
- BRIACELL THERAPEUTICS CORP.: operating expenses
- BRIACELL THERAPEUTICS CORP.: research and development expense
Inspect the source
- Entity
- BRIACELL THERAPEUTICS CORP. / CIK 0001610820
- Captured
- 2026-09-20T09:26:46.138Z
- SEC response SHA-256
9b120e952e46202c087d84b15420884d11dabee9617ee209952acee5219f65e1
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001610820.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))